vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
Beta Bionics, Inc. is the larger business by last-quarter revenue ($27.6M vs $19.1M, roughly 1.4× Americas Gold & Silver Corp). Beta Bionics, Inc. runs the higher net margin — -79.3% vs -82.3%, a 3.1% gap on every dollar of revenue. On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs -28.0%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
BBNX vs USAS — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $19.1M |
| Net Profit | $-21.9M | $-15.7M |
| Gross Margin | 59.5% | 34.2% |
| Operating Margin | -47.4% | — |
| Net Margin | -79.3% | -82.3% |
| Revenue YoY | 56.6% | -28.0% |
| Net Profit YoY | 23.6% | 2.8% |
| EPS (diluted) | $-0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | — | ||
| Q3 25 | $27.3M | $19.1M | ||
| Q2 25 | $23.2M | — | ||
| Q1 25 | $17.6M | — | ||
| Q3 24 | — | $26.5M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-14.2M | $-15.7M | ||
| Q2 25 | $-16.9M | — | ||
| Q1 25 | $-28.7M | — | ||
| Q3 24 | — | $-16.2M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | — | ||
| Q3 25 | 55.5% | 34.2% | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 50.9% | — | ||
| Q3 24 | — | 23.6% |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | — | ||
| Q3 25 | -62.5% | — | ||
| Q2 25 | -85.5% | — | ||
| Q1 25 | -105.7% | — | ||
| Q3 24 | — | — |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | — | ||
| Q3 25 | -52.1% | -82.3% | ||
| Q2 25 | -72.6% | — | ||
| Q1 25 | -162.5% | — | ||
| Q3 24 | — | -60.9% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.33 | — | ||
| Q2 25 | $-0.39 | — | ||
| Q1 25 | $-0.93 | — | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $39.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $271.2M | $50.2M |
| Total Assets | $304.4M | $234.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | — | ||
| Q3 25 | $228.7M | $39.1M | ||
| Q2 25 | $249.7M | — | ||
| Q1 25 | $231.5M | — | ||
| Q3 24 | — | — |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | — | ||
| Q3 25 | $294.8M | $50.2M | ||
| Q2 25 | $301.6M | — | ||
| Q1 25 | $313.8M | — | ||
| Q3 24 | — | $53.1M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | — | ||
| Q3 25 | $330.0M | $234.7M | ||
| Q2 25 | $330.0M | — | ||
| Q1 25 | $338.0M | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-12.5M |
| Free Cash FlowOCF − Capex | — | $-41.3M |
| FCF MarginFCF / Revenue | — | -216.5% |
| Capex IntensityCapex / Revenue | — | 150.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $-8.7M | $-12.5M | ||
| Q2 25 | $-13.6M | — | ||
| Q1 25 | $-20.0M | — | ||
| Q3 24 | — | $2.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | — | ||
| Q3 25 | $-10.0M | $-41.3M | ||
| Q2 25 | $-15.4M | — | ||
| Q1 25 | $-20.3M | — | ||
| Q3 24 | — | $-11.2M |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | — | ||
| Q3 25 | -36.7% | -216.5% | ||
| Q2 25 | -66.2% | — | ||
| Q1 25 | -115.1% | — | ||
| Q3 24 | — | -42.2% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | — | ||
| Q3 25 | 4.7% | 150.8% | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 1.9% | — | ||
| Q3 24 | — | 51.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
